Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

Cancer Cell

Volumn 21, Issue 4, 2012, Pages 488-503

  Nakasone, Elizabeth S ^a,b   Askautrud, Hanne A ^a,c,d,e   Kees, Tim ^a   Park, Jae Hyun ^a   Plaks, Vicki ^c   Ewald, Andrew J ^c,f   Fein, Miriam ^a,g   Rasch, Morten G ^a,h   Tan, Ying Xim ^c   Qiu, Jing ^a   Park, Juwon ^a   Sinha, Pranay ^a   Bissell, Mina J ⁱ   Frengen, Eirik ^d,e   Werb, Zena ^c   Egeblad, Mikala ^a,c  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b WATSON SCHOOL OF BIOLOGICAL SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h FINSEN LABORATORY   (Denmark)

ⁱ LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CISPLATIN; DOXORUBICIN; GELATINASE B;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW CELL; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL INFILTRATION; CELL INTERACTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; SPINNING DISK CONFOCAL MICROSCOPY; STROMA CELL; TUMOR MICROENVIRONMENT; VASCULAR DISEASE; VASCULAR LEAKAGE;

MUS;

EID: 84859820567     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.02.017     Document Type: Article

References (44)

1. Ahn G.O., Tseng D., Liao C.H., Dorie M.J., Czechowicz A., Brown J.M. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl. Acad. Sci. USA 2010, 107:8363-8368.
2. Campiglio M., Somenzi G., Olgiati C., Beretta G., Balsari A., Zaffaroni N., Valagussa P., Ménard S. Role of proliferation in HER2 status predicted response to doxorubicin. Int. J. Cancer 2003, 105:568-573.
3. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
4. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
5. Denardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
6. Dive C., Gregory C.D., Phipps D.J., Evans D.L., Milner A.E., Wyllie A.H. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim. Biophys. Acta 1992, 1133:275-285.
7. Ebrahem Q., Chaurasia S.S., Vasanji A., Qi J.H., Klenotic P.A., Cutler A., Asosingh K., Erzurum S., Anand-Apte B. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am. J. Pathol. 2010, 176:496-503.
8. Egeblad M., Ewald A.J., Askautrud H.A., Truitt M.L., Welm B.E., Bainbridge E., Peeters G., Krummel M.F., Werb Z. Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis. Model Mech. 2008, 1:155-167.
9. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 2010, 18:884-901.
10. Fujimoto H., Sangai T., Ishii G., Ikehara A., Nagashima T., Miyazaki M., Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int. J. Cancer 2009, 125:1276-1284.
11. Gavard J. Breaking the VE-cadherin bonds. FEBS Lett. 2009, 583:1-6.
12. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
13. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
14. Gong Y., Hart E., Shchurin A., Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J. Clin. Invest. 2008, 118:3012-3024.
15. Greene R.F., Collins J.M., Jenkins J.F., Speyer J.L., Myers C.E. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. 1983, 43:3417-3421.
16. Guerriero J.L., Ditsworth D., Catanzaro J.M., Sabino G., Furie M.B., Kew R.R., Crawford H.C., Zong W.X. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J. Immunol. 2011, 186:3517-3526.
17. Hadjantonakis A.K., Papaioannou V.E. Dynamic in vivo imaging and cell tracking using a histone fluorescent protein fusion in mice. BMC Biotechnol. 2004, 4:33.
18. Hagendoorn J., Tong R., Fukumura D., Lin Q., Lobo J., Padera T.P., Xu L., Kucherlapati R., Jain R.K. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 2006, 66:3360-3364.
19. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8:R76.
20. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., Sausville E.A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84:1424-1431.
21. Lin E.Y., Jones J.G., Li P., Zhu L., Whitney K.D., Muller W.J., Pollard J.W. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 2003, 163:2113-2126.
22. Loberg R.D., Ying C., Craig M., Day L.L., Sargent E., Neeley C., Wojno K., Snyder L.A., Yan L., Pienta K.J. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007, 67:9417-9424.
23. Loeffler M., Krüger J.A., Niethammer A.G., Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 2006, 116:1955-1962.
24. Martin M.D., Carter K.J., Jean-Philippe S.R., Chang M., Mobashery S., Thiolloy S., Lynch C.C., Matrisian L.M., Fingleton B. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res. 2008, 68:6251-6259.
25. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
26. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6:583-592.
27. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
28. Netti P.A., Hamberg L.M., Babich J.W., Kierstead D., Graham W., Hunter G.J., Wolf G.L., Fischman A., Boucher Y., Jain R.K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA 1999, 96:3137-3142.
29. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
30. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
31. Pahler J.C., Tazzyman S., Erez N., Chen Y.Y., Murdoch C., Nozawa H., Lewis C.E., Hanahan D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340.
32. Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., Johnson M., Lusis A.J., Cohen D.A., Iruela-Arispe M.L., Wu L. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471.
33. Rasch M.G., Lund I.K., Illemann M., Høyer-Hansen G., Gårdsvoll H. Purification and characterization of recombinant full-length and protease domain of murine MMP-9 expressed in Drosophila S2 cells. Protein Expr. Purif. 2010, 72:87-94.
34. Rottenberg S., Pajic M., Jonkers J. Studying drug resistance using genetically engineered mouse models for breast cancer. Methods Mol. Biol. 2010, 596:33-45.
35. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11:5678-5685.
36. Sadik C.D., Kim N.D., Luster A.D. Neutrophils cascading their way to inflammation. Trends Immunol. 2011, 32:452-460.
37. Shree T., Olson O.C., Elie B.T., Kester J.C., Garfall A.L., Simpson K., Bell-McGuinn K.M., Zabor E.C., Brogi E., Joyce J.A. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25:2465-2479.
38. Sounni N.E., Dehne K., van Kempen L., Egeblad M., Affara N.I., Cuevas I., Wiesen J., Junankar S., Korets L., Lee J., et al. Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis. Model Mech. 2010, 3:317-332.
39. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., McDonald D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514.
40. Tsou C.L., Peters W., Si Y., Slaymaker S., Aslanian A.M., Weisberg S.P., Mack M., Charo I.F. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 2007, 117:902-909.
41. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
42. Welford A.F., Biziato D., Coffelt S.B., Nucera S., Fisher M., Pucci F., Di Serio C., Naldini L., De Palma M., Tozer G.M., Lewis C.E. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011, 121:1969-1973.
43. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
44. Zhang J., Lu Y., Pienta K.J. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J. Natl. Cancer Inst. 2010, 102:522-528.